Estradiol benzoate butyrate

rdf:langString Estradiol benzoate butyrate

rdf:langString Estradiol benzoate butyrate molecule ball.png

rdf:langString [-17-butanoyloxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate

rdf:langString CCCCO[C@H]1CC[C@@H]2[C@@]1C

rdf:langString MKYFGNOOEKZNPW-ZRJUGLEFSA-N

rdf:langString EBB; Estradiol 3-benzoate 17β-n-butyrate; Estra-1,3,5-triene-3,17β-diol 3-benzoate 17β-n-butyrate

rdf:langString Neolutin N, Redimen, Soluna, Unijab

rdf:langString ZE4IGI4UMH

rdf:langString Estradiol benzoate butyrate (EBB), sold under the brand names Neolutin N, Redimen, Soluna, and Unijab and formerly known under the developmental code name Unimens, is an estrogen medication which is used in hormonal birth control for women. It is formulated in combination with dihydroxyprogesterone acetophenide (DHPA; algestone acetophenide), a progestin, and is used specifically as a combined injectable contraceptive. EBB is not available for medical use alone. The medication, in combination with DHPA, is given by injection into muscle once a month. Side effects of EBB include breast tenderness, breast enlargement, nausea, headache, and fluid retention. EBB is an estrogen and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It is an estrogen ester and a prodrug of estradiol in the body. Because of this, it is considered to be a natural and bioidentical form of estrogen. EBB was first described in 1938. It was developed for use as a form of birth control in the 1970s and was introduced for medical use for this indication by the 1980s. The medication is used in combination with DHPA as a combined injectable contraceptive in Peru and Singapore.

rdf:langString Neolutin N, Redimen, Soluna, Unijab (all combinations)